Urologic Nursing - Levaquin[R] receives FDA approval for treatment of chronic bacterial prostatitis.(New Products)(Brief Article)
The U.S. Food and Drug Administration (FDA) has approved Levaquin[R] (levofloxacin) Tablets/Injection and Levaquin[R] (levofloxacin in 5% dextrose) Injection for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis or Staphylococcus epidermidis. Chronic bacterial prostatitis is a recurrent or persistent infection of the prostate gland and the number one reason men under the age of 50 visit a urologist. With this indication, Levaquin becomes the only once-daily fluoroquinolone indicated to treat chronic bacterial prostatitis.
Most Popular
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
3 Questions No Job Seeker Ever Wants To Be Asked?
Levaquin is …
Read the rest of this article with a Free Trial at HighBeam Research.
